9 Pancreatic Cancer Clinical Trials in Chicago, IL (2026)

Q: How do I join a clinical trial in Chicago?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you.

Recruiting Pancreatic Cancer Studies in Chicago

NCT07307664Recruiting

Increasing Germline Genetic Testing for Patients With Cancer

Germline testing for hereditary cancer syndromes is underutilized across most health care settings. Using a learning health care approach, the Genomics-enabled Learning Health Systems (gLHS) network a...

Chicago, ILNA1,000 participantsJosh Peterson

View Study Details

NCT07621718Recruiting

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy....

Chicago, ILPHASE3670 participantsRevolution Medicines, Inc.

View Study Details

NCT07562152Recruiting

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone....

Chicago, ILPHASE3510 participantsImmuneering Corporation

View Study Details

NCT05968326Recruiting

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRIN...

Chicago, ILPHASE2260 participantsGenentech, Inc.

View Study Details

NCT06922591Recruiting

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236 or...

Chicago, ILPHASE1183 participantsTango Therapeutics, Inc.

View Study Details

NCT04172532Recruiting

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that h...

Chicago, ILPHASE192 participantsNational Cancer Institute (NCI)

View Study Details

NCT02843945Recruiting

Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal....

Chicago, ILPHASE180 participantsCivaTech Oncology

View Study Details

NCT04361708Recruiting

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

The purpose of the proposed study is to establish the safety of combining irinotecan chemotherapy with 5-FU, leucovorin/folinic acid, oxaliplatin, and docetaxel (abbreviated as the I-FLOAT study of gF...

Chicago, ILPHASE154 participantsUniversity of Chicago

View Study Details

NCT04048278Recruiting

Lidocaine Infusion in Pancreatic Cancer

This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for al...

Chicago, ILEARLY_PHASE146 participantsUniversity of Illinois at Chicago

View Study Details

About Pancreatic Cancer Clinical Trials in Chicago

Pancreatic cancer begins in the tissues of the pancreas and is often diagnosed at an advanced stage. It is one of the most challenging cancers to treat. Clinical trials are actively investigating new approaches including immunotherapy and combination regimens.

There are currently 9 pancreatic cancer clinical trials recruiting participants in Chicago, IL. These studies are seeking a combined 2,895 participants. Research is being sponsored by Josh Peterson, Revolution Medicines, Inc., Immuneering Corporation and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pancreatic Cancer Clinical Trials in Chicago — FAQ

Are there pancreatic cancer clinical trials in Chicago?

Yes, there are 9 pancreatic cancer clinical trials currently recruiting in Chicago, IL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chicago?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.

Are clinical trials in Chicago free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.

What pancreatic cancer treatments are being tested?

The 9 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for pancreatic cancer.

Data updated July 16, 2026 from ClinicalTrials.gov